07
Apr

A transatlantic group of venture investors crowded into a $120 million venture round for Vienna-based Nabriva Therapeutics, offering enough cash to get started with a Phase III study for a new antibiotic.

…read more

Source: Nabriva preps for PhIII antibiotic trial with a $120M VC commitment

    

0 No comments